ClinicalTrials.gg
RecruitingNCT07664553Eluminate-3Updated Aug 4, 2026

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin

A Phase 3 interventional study of Elecoglipron and Placebo in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Recruiting at 132 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 6 of them phase 3. elecoglipron · Diabetes Mellitus, Type 2.

Planned enrollment
5th of 18
600 · median 57
Started
2026
with 8 others
Phase 3
6 of 18
6 open now
Registered
13th of 18
by date
Lead sponsor
14 of 18
AstraZeneca

Among the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, this one is the 5th largest by planned enrollment, is one of 9 that started in 2026, is one of 6 in phase 3, and was the 13th registered.

Diabetes Mellitus, Type 2

10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About elecoglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults with Type 2 Diabetes Mellitus (T2DM), treated with a background insulin and other background glucose-lowering medication(s)

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with T2DM for at least 90 days prior to screening
  • Stable treatment with background insulin and other background glucose-lowering medication(s)
  • value of ≥ 7% to ≤ 10.5%
  • (BMI) of ≥ 23 kg/m2 at screening
  • Stable body weight (self-reported or documented) for 90 days prior to screening

Exclusion criteria

Exclusion Criteria:

  • T1DM, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma
  • Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema
  • Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
  • condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying
  • History of acute or chronic pancreatitis.
  • Severe congestive heart failure ( IV)
  • History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Elecoglipron dose level 1

    Participants will receive elecoglipron at dose level 1 administered orally once daily.

    Drug: Elecoglipron

  • Experimental
    Elecoglipron dose level 2

    Participants will receive elecoglipron at dose level 2 administered orally once daily.

    Drug: Elecoglipron

  • Placebo comparator
    Placebo

    Participants will receive placebo administered orally once daily.

    Drug: Placebo

Interventions

  • Elecoglipron is administered orally once daily.

  • DrugPlacebo

    Placebo is administered orally once daily.

06

What researchers measure

Primary outcomes

  1. Change from baseline in Hemoglobin A1c (HbA1c)

    Summary statistics

    Time frame: Baseline to Week 40

Secondary outcomes

  1. Achieved HbA1c < 7% (53 mmol/mol) at Week 40

    Time frame: Week 40

  2. Achieved HbA1c ≤ 6.5% (48 mmol/mol) at Week 40

    Time frame: Week 40

  3. Percent change from baseline to Week 40 in body weight

    Time frame: Baseline to Week 40

  4. Change from baseline to Week 40 in body weight (kg)

    Time frame: Baseline to Week 40

  5. Change from baseline to Week 40 in Systolic blood pressure (SBP)

    Time frame: Baseline to Week 40

  6. Change from baseline to Week 40 in fasting plasma glucose (FPG)

    Time frame: Baseline to Week 40

  7. Achieved HbA1c < 7% (53 mmol/mol) at Week 40 without hypoglycemia (glucose < 54 mg/dL [3.0 mmol/L] or severe hypoglycemia)

    Time frame: Baseline to Week 40

  8. Change from baseline to Week 40 in daily mean 7-point self-monitoring blood glucose (SMBG)

    Time frame: Baseline to Week 40

  9. Change from baseline to Week 40 in diastolic blood pressure (DBP)

    Time frame: Baseline to Week 40

  10. Change from baseline to Week 40 in total daily insulin dose (IU)

    Time frame: Baseline to Week 40

  11. Discontinued insulin by Week 40

    Time frame: Baseline to Week 40

07

Study locations

6 of 132 sites recruiting
  • Research Site
    Little Rock, Arkansas 72205, United States
    Not yet recruiting
  • Research Site
    Sacramento, California 95821, United States
    Not yet recruiting
  • Research Site
    Aurora, Colorado 80045, United States
    Not yet recruiting
  • Research Site
    DeLand, Florida 32720, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Doral, Florida 33166, United States
    Not yet recruiting
  • Research Site
    Ocoee, Florida 34761, United States
    Recruiting
  • Research Site
    Decatur, Georgia 30030, United States
    Not yet recruiting
  • Research Site
    Potomac, Maryland 20854, United States
    Not yet recruiting
  • Research Site
    Brooklyn, New York 11220, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Cary, North Carolina 27518, United States
    Not yet recruiting
  • Research Site
    Morehead City, North Carolina 28557, United States
    Not yet recruiting
  • Research Site
    Myrtle Beach, South Carolina 29572, United States
    Not yet recruiting
  • Research Site
    Memphis, Tennessee 38119, United States
    Not yet recruiting
  • Research Site
    Houston, Texas 77040, United States
    Not yet recruiting
  • Research Site
    Round Rock, Texas 78681, United States
    Not yet recruiting
  • Research Site
    San Antonio, Texas 78231, United States
    Not yet recruiting
  • Research Site
    Renton, Washington 98057, United States
    Not yet recruiting
  • Research Site
    Campbelltown, 2560, Australia
    Not yet recruiting
  • Research Site
    East Toowoomba, 4350, Australia
    Recruiting
  • Research Site
    Heidelberg Heights, 3081, Australia
    Not yet recruiting
  • Research Site
    Parkville, 3050, Australia
    Not yet recruiting
  • Research Site
    St Leonards, 2065, Australia
    Not yet recruiting
  • Research Site
    Dupnitsa, 2600, Bulgaria
    Not yet recruiting
  • Research Site
    Kozloduy, 3320, Bulgaria
    Not yet recruiting
  • Research Site
    Plovdiv, 4001, Bulgaria
    Not yet recruiting
  • Research Site
    Sofia, 1618, Bulgaria
    Not yet recruiting
  • Research Site
    Stara Zagora, 6000, Bulgaria
    Not yet recruiting
  • Research Site
    Veliko Tarnovo, 5000, Bulgaria
    Not yet recruiting
  • Research Site
    Yambol, 8600, Bulgaria
    Not yet recruiting
  • Research Site
    Surrey, British Columbia V3T 4G8, Canada
    Not yet recruiting
  • Research Site
    Vancouver, British Columbia V5Y 3W2, Canada
    Recruiting
  • Research Site
    Brampton, Ontario L6S 0C6, Canada
    Not yet recruiting
  • Research Site
    North York, Ontario M6B 3H7, Canada
    Not yet recruiting
  • Research Site
    Sarnia, Ontario N7T 4X3, Canada
    Not yet recruiting
  • Research Site
    Scarborough Village, Ontario M1R 0B1, Canada
    Not yet recruiting
  • Research Site
    Toronto, Ontario M4G3E8, Canada
    Recruiting
  • Research Site
    Saint-Charles-Borromée, Quebec J6E 2B4, Canada
    Not yet recruiting
  • Research Site
    Changsha, 410013, China
    Not yet recruiting
  • Research Site
    Changsha, 410015, China
    Not yet recruiting
  • Research Site
    Hefei, 230000, China
    Not yet recruiting
  • Research Site
    Hefei, 230601, China
    Not yet recruiting
  • Research Site
    Huai'an, 223005, China
    Not yet recruiting
  • Research Site
    Langfang, 065000, China
    Not yet recruiting
  • Research Site
    Liangyugang, 222002, China
    Not yet recruiting
  • Research Site
    Luoyang, 471009, China
    Not yet recruiting
  • Research Site
    Nanjing, 2100008, China
    Not yet recruiting
  • Research Site
    Nanyang, 473009, China
    Not yet recruiting
  • Research Site
    Pinggu, 101200, China
    Not yet recruiting
  • Research Site
    Pingxiang, 337055, China
    Not yet recruiting
  • Research Site
    Shijiazhuang, 050000, China
    Not yet recruiting
  • Research Site
    Tianjin, 300134, China
    Not yet recruiting
  • Research Site
    Yueyang, 414000, China
    Not yet recruiting
  • Research Site
    Broumov, 55001, Czechia
    Not yet recruiting
  • Research Site
    České Budějovice, 370 01, Czechia
    Not yet recruiting
  • Research Site
    Ostrava, 710 00, Czechia
    Not yet recruiting
  • Research Site
    Pilsen, 301 00, Czechia
    Not yet recruiting
  • Research Site
    Prague, 140 00, Czechia
    Not yet recruiting
  • Research Site
    Prague, 170 00, Czechia
    Not yet recruiting
  • Research Site
    Prague, 181 00, Czechia
    Not yet recruiting
  • Research Site
    Amberg, 92224, Germany
    Not yet recruiting
  • Research Site
    Bad Oeynhausen, 32545, Germany
    Not yet recruiting
  • Research Site
    Berlin, 13597, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Bochum, 44869, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Brandenburg an der Havel, 14776, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Daaden, 57567, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Duisburg, 47051, Germany
    Not yet recruiting
  • Research Site
    Eisenach, 99817, Germany
    Not yet recruiting
  • Research Site
    Elsterwerda, 04910, Germany
    Not yet recruiting
  • Research Site
    Falkensee, 14612, Germany
    Not yet recruiting
  • Research Site
    Frankfurt, 60596, Germany
    Not yet recruiting
  • Research Site
    Fulda, 36037, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Gladbeck, 45968, Germany
    Not yet recruiting
  • Research Site
    Hamburg, 22607, Germany
    Not yet recruiting
  • Research Site
    Hannoversch Münden, 34346, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Magdeburg, 39120, Germany
    Not yet recruiting
  • Research Site
    Mannheim, 68167, Germany
    Not yet recruiting
  • Research Site
    Münster, 48153, Germany
    Not yet recruiting
  • Research Site
    Nittendorf, 93152, Germany
    Not yet recruiting
  • Research Site
    Obertshausen, 63179, Germany
    Not yet recruiting
  • Research Site
    Oldenburg, 23758, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Pirna, 01796, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Bangalore, 560 092, India
    Not yet recruiting
  • Research Site
    Belagavi, 590006, India
    Not yet recruiting
  • Research Site
    Chennai, 600086, India
    Not yet recruiting
  • Research Site
    Coimbatore, 641018, India
    Not yet recruiting
  • Research Site
    Guntur, 522001, India
    Not yet recruiting
  • Research Site
    Hyderabad, 500034, India
    Not yet recruiting
  • Research Site
    Indore, 452008, India
    Not yet recruiting
  • Research Site
    Kochi, 682041, India
    Not yet recruiting
  • Research Site
    Madurai, 625020, India
    Not yet recruiting
  • Research Site
    Mumbai, 400012, India
    Not yet recruiting
  • Research Site
    New Delhi, 110029, India
    Not yet recruiting
  • Research Site
    Pune, 411021, India
    Not yet recruiting
  • Research Site
    Asahikawa-shi, 070-8530, Japan
    Not yet recruiting
  • Research Site
    Kamakura-shi, 247-0056, Japan
    Not yet recruiting
  • Research Site
    Kashiwa-shi, 277-0825, Japan
    Not yet recruiting
  • Research Site
    Kobe, 650-0047, Japan
    Not yet recruiting
  • Research Site
    Komoro, 384-8588, Japan
    Not yet recruiting
  • Research Site
    Kumamoto, 862-0976, Japan
    Not yet recruiting
  • Research Site
    Kyoto, 606-8507, Japan
    Not yet recruiting

Showing the first 100 of 132 sites across 13 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for May 2028, 22 months after the start.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's planned 22 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2026
First posted
Jun 24, 2026
StartActual
Jul 8, 2026
Primary completionEst.
May 23, 2028
CompletionEst.
May 23, 2028
Last update
Aug 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07664553
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 24, 2026
Start date
Jul 8, 2026
Primary completion
May 23, 2028 (estimated)
Completion
May 23, 2028 (estimated)
Last update
Aug 4, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elecoglipron

Start the discussion